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PSYCHIATRY

Practica
Approaches to
Treating
Patients with
Bipolar
Disorder
Jane E. Neu, MSN, FNP, APRN,BC and
Susan DeNisco, MS, FNP, APRN,BC

Many patients present to a primary care setting with symptoms
of a mood disorder. These symptoms may be indicative of an
anxiety disorder or a depressive
disorder, but they may also represent bipolar disorder, which is
more common than many practitioners think. Correctly diagnosing bipolar disorder can be
complex, because patients tend to
seek treatment when they are
experiencing the symptoms of
depression or anxiety rather than
mania or hypomania. Comorbid
disorders such as substance abuse
and anxiety disorders may complicate the clinical presentation.

Failing to correctly diagnose
bipolar disorder can have serious
consequences in terms of patients'
morbidity and mortality, quality
of life, and financial costs.
Primary care nurse practitioners
(NPs) frequently see patients who
have both medical and psychiatric
diagnoses.'' The psychiatric diagnosis may present in a variety of
guises and may be hidden under
an array of sonnatic complaints.'
Mentally healthy individuals experience a vast range of moods
throughout their lifetime; this normal fluctuation may fall between
euphoria and depression. However, extreme mood swings may
alter a person's thoughts, feelings.
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physical health, behavior, and
social functioning, and may represent a more serious cause such as
unipolar depression (ie, major
depression) or bipolar disorder
(alternation between elevated and
depressed mood states).^'
Because of the limited time
frame available to evaluate each
patient, NPs may have difficulty
distinguishing betv^ieen a normal
fluctuation of mood and a more
extreme fluctuation of mood
indicative of a more serious psychiatric disorder.' As providers of
holistic care, as well as being the
sole healthcare providers that many
patients see, NPs are responsible
for recognizing, diagnosing, and
treating mental illnesses, as well as
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making appropriate referrals.' The
diagnosis of bipolar disorder is
often under-recognized because
patients tend to report depression,
anxiety, insomnia, or substance
abuse, while ignoring their episodes of mania or hypomania.''^
• Unipolar depression: loss of
interest or pleasure in all or
almost all activities most of the
day, nearly every day; changes
in appetite and v^^eight;
decreased energy, concentration and memory; increased
feelings of hopelessness, helplessness, guilt, fatigue, irritability or restiessness;
• Anxiety: excessive worry that
is difficult to control and is
associated with restlessness,
fatigue, poor concentration,
irritability, muscle tension
and sleep disturbance;
• Mania: abnormally elevated,
expansive, or irritable mood
characterized by grandiosity,
decreased need for sleep, pressured speech, flight of ideas,
distraaibility, psychomotor
agitation, and excessive involvement in pleasurable
activities without regard to the
consequences; and
• Hypomania: an abnormality
of mood resembling mania
but of lesser intensity.'
If patients are experiencing
acute mania or hypomania, which
might signal a diagnosis of bipolar
disorder, they are more likely to
present to an emergency department (ED) rather than to a primary
care setting.''^

Historical Overview of
Mood Disorders
Reviewing the history of mood disorders provides insight into the

persisting stigmata associated with depression." In 1921, Emil Kraepelin
mental illness. Mood disorders published Manic-Depressive Insanity
were initially described by the and Paranoia, which suggested for the
ancient Greeks and Romans, who firsttimethat severe psychotic deprescoined tbe terms mania and melan- sion could have altemating forms of
cholia and identified them as two mania and severe melancholy." Since
distinct disorders."' One treatment then, the complicated subtypes of
recommended for euphoric, agitat- bipolar disorder have been identified
ed, or melancholic patients was and diagnostic criteria established.
bathing in the waters of northern
Italian spas. A natural supply of Incidence
lithium salts was later discovered to Each year, 20% to 23% of US
be present in these waters.**
adults suffer from depression and
In 300 BC, Hippocrates des- 38% from an anxiety disorder."'*
cribed the link between "the four The incidence of bipolar I disorder
humors"—which he labeled blood, is approximately 1%,'"'"' but if the
black bile, yellow bile, and broader spectrum of bipolar disorphlegm—and physical health.'" ders is included, then the incidence
Hippocrates' support of the physi- may be as high as 8%,"^^' leading
cal origin of mental disorders was the World Health Organization
contrary to the popular belief of (WHO) to identify bipolar disorthe time period—that mental ill- der as the sixth leading cause of
ness was caused by magical or disability for persons aged 15 to
supernatural forces.*
65.'"" Two thirds of patients with
In the second century AD, bipolar disorder have impairment
Areteus of Cappadocia thought in both occupational and functionthat euphoria and depression al domains, and instability in
might coexist as two attributes of social and intimate relationships.
one disorder."'"" After the decline
Bipolar disorder is equally comof the Roman Empire, devil pos- mon in men and women,^'"'
session was believed to be the although research indicates that
cause of mania and depression. women are 3 times more likely
Treatments included restraints, than men to experience rapid
euthanasia, exotic potions, blood- cycling."-^" Further studies have
letting, and application of electric indicated that bipolar II disorder
eels to the skull."
may be more common in women
than
in men.'"^* The incidence of
The term manico-melancolicus
bipolar
disorder in children and
was coined by Théophile Bonet in
adolescents
is more difficult to
1686 to describe the relationship
determine.
In
the past, this disorder
between mania and melancholia."
was
thought
to
be rare or nonexisA more modem conceptualization
tent
in
children."
Findings in one
was described by lean-Pierre Fairet
National
Institute
of
Mental Health
in the 1850s as folie circulaire,
(NIMH)
study
suggested
that bipomeaning "circular insanity"; folie
lar
disorder
was
as
common
in
can also mean "double form,"
young
people
as
it
is
in
adults."
A
which describes the attacks of both
study
on
82
children
with
pédiatrie
mania and depression that characterize bipolar disorder."'^ This early bipolar disorder (mean age, 11
identification encompassed a wide years), showed that in 74% of the
range of affective disorders that participants, psychopathologic
included unipolar and bipolar manifestations such as mood and
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sleep disturbances, hyperactivity,
aggression, and anxiety v^^ere recognized before age 3 years." Ninety
percent of the participants had a
family history of mood or substance abuse disorders."

the pathophysiology of bipolar
disorder is limited.^" Several different neurotransmitters have been
linked to bipolar disorder; these
links have been based on patients'
responses to psychoactive agents.
For example, patients treated with
reserpine incidentally experience
Etiology and Pathophysiology
The etiology of bipolar disorder is depression. Because reserpine depletes catecholamines from nerve
complex, and seems to be related
tissues, researchers hypothesized
to the interaction of various genetthat an increase in epinephrine
ic and non-genetic factors.^^'^" The
and norepinephrine induces
genetic link has been suggested by mania, whereas a decrease in these
the results of family, twin, and neurotransmitters causes depresadoption studies. "'^^^'' First-degree sion. Cocaine, another drug that
relatives of a person with bipolar acts on this neurotransmitter sysdisorder, as compared with the tem, exacerbates mania. Levodopa
general population, are approxi- also exacerbates mania, suggesting
mately 7 times more likely to that dopamine and serotonin are
develop the disorder. ^^
linked to bipolar disorder. Finally,
Despite the identification of a hormonal imbalances and disrupgenetic link, the understanding of tions of the hypothalamic-pitu-

TABLE 1

BIPOLAR SPECTRUM DISORDERS'

BIPOLAR I DISORDER: Presence or history of at least one manic episode,
with or without o history of major depressive episode(s) that cannot be
accounted for by another disorder; the episode must have lasted at least a
week (unless functional impairment is so great that hospitalization is
required)
BIPOLAR II DISORDER: Presence or history of at least one hypomanic
episode and one or more major depressive episode(s) that cannot be
accounted for by another disorder
•

CYCLOTHYMIA: Presence of numerous periods of hypomanic symptoms
interspersed with numerous periods of depressive symptoms, but to a
lesser degree than those occurring with bipolar I or bipolar II, and
occurring almost consistently during a 2-year time period (1 year of
symptoms in children and adolescents)

•

BIPOLAR DISORDER, NOT OTHERWISE SPECIFIED: Residual diagnostic
category for bipolar features that do not meet diagnostic criteria for bipolar
I, bipolar II, or cyclothymia. This diagnostic category may be used during
the period of initial diagnosis if a secondary cause for the symptoms such
as substance abuse or a medical condition is being considered.

Adapted from American Psychiatric Association, Diagnostic and Sfafisficai Manuai of Mentai
Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association;
2000:375-376.
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itary-adrenal axis may contribute
to the clinical presentation of bipolar disorder.^"
Non-genetic factors, including
psychological stress, thyroid disease, and sleep deprivation, may be
closely intertwined with a genetic
predisposition to bipolar disorder.""'" One psychodynamic theory identifies the depressive side of
the disorder as a manifestation of
losses, and the manic side as a
defense against depression,^"

Definitions and Diagnostic Criteria
The Diagnostic and Statistical
Manual of Mental Disorders, Fourth
Edition, Text Revision (DSM-IV-TR)

identifies the criteria used to diagnose bipolar I disorder, bipolar II
disorder, cyclothymia, and bipolar
disorder, not otherwise specified
(NOS) (Table 1)."^ To increase
recognition of bipolar disorder, this
diagnosis should be considered in
all patients who present with symptoms of a mood disorder.^ '° Specific
features provide clues to making
an accurate diagnosis. Red nags
include a family history of bipolar
disorder, an early age of onset (<25
years), frequent episodes, rapid
cycling, psychotic features, seasonal
patterns, and poor response to
antidepressants (eg, treatmentemergent hypomania, lack of
response to multiple trials of different antidepressants).'''''"*
In children and adolescents,
NPs need to distinguish bipolar
disorder from other behavioral disorders. Red flags for identifying
bipolar disorder in children and
adolescents include infiated selfesteem or grandiosity, increased
goal-directed activity,flightof ideas,
decreased need for sleep, excessive
involvement in pleasurable activities without concern for adverse
consequences, and pronounced
se}aial energy."
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The Mood Disorder Questionnaire (MDQ) is a validated screening tool for bipolar depression
(Table 2).^*^ This questionnaire can
help identify 70% of patients with
bipolar disorder while eliminating the diagnosis in 90% of persons without the diagnosis. The
MDQ is easily administered by
primary care providers or it can be
self-administered by patients. It
contains 15 questions focusing on
behavioral symptoms and on the
family and personal history. The
test takes about 5 minutes to complete. Some patients may have
only 3 or 4 positive answers to the
MDQ, which is insufficient to
meet criteria for bipolar disorder
(7 of 13 positive answers). Nevertheless, in these cases, NPs should
be alert for future manifestations
of this illness. The MDQ has
another important function—it
may make patients more aware of
symptoms that they may have disregarded in the past.^

Distinguishing Bipolar
Depression from Unipolar
Depression in Adults
Bipolar disorder is a complicated
diagnosis because of the lack of a
consistent pattern of presentation.
Differentiating bipolar depression
from unipolar depression is a challenge; misdiagnosis is common. A
chart review of 85 patients with
bipolar or unipolar depression
showed that 56% of the patients
were originally misdiagnosed,"
usually with unipolar depression
or an anxiety disorder.^ '"*'^'*
Comorbid psychiatric conditions may obscure the clinical picture, adding to the difficulty of
making an accurate diagnosis."'^'
Sixty-five percent of bipolar
patients have a comorbid psychiatric axis I disorder (ie, a major

mental disorder such as depression, anxiety, schizophrenia, attention-deficit hyperactivity disorder,
post-traumatic stress disorder) and
25% have three or more diagnoses." An NIMH study of patients
with bipolar disorder showed that
42% also met criteria for post-traumatic stress disorder.'" Underlying
personality disorders also complicate the picture—many features of
bipolar disorder and borderline
personality disorder overlap.^""
Finally, approximately 60% of
patients with bipolar disorder selfmedicate with alcohol, marijuana,
or other illicit substances, making
accurate diagnosis of bipolar disorder even more complicated.^ '^'
Many patients with bipolar
disorder function adequately in
their social life and view their
hypomanic periods as productive." Thus, they tend to seek medical care only during the depressed
phase of their illness. When
patients are depressed, they may
be unable to recall episodes of
feeling good."' NPs need to bear
in mind that a depressed mood
may not be specific to a depressive
disorder but may also occur transitionally during a manic episode or
pervasively." Therefore, bipolar
disorder needs to be included in
the differential diagnosis whenever a patient presents with symptoms of depression.

Distinguishing Bipolar Disorder
from Behavior Disorders in
Children and Adolescents
Identifying bipolar disorder in
young persons is complicated by
the fact that the diagnostic criteria
are based on symptoms found in
adults (research on age-appropriate criteria is limited)."" Manifestations of bipolar disorder
typically appear during the teenage
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years or early 20s (median age of
onset, 17.5 years).'"•'"^'"^••''•"
One challenge in recognizing
bipolar disorder in children and
adolescents is that they may present with disruptive behaviors that
can be confused with attention
deficit hyperactivity disorder
(ADHD), oppositional defiant disorder (ODD), or conduct disorder
(CD)."""" Also, certain manifestations of bipolar disorder (eg,
excessive talking, distractibility,
increased activity level, restlessness, loss of normal social inhibitions) overlap with those of
ADHD. Furthermore, the diagnoses of ADHD and bipolar disorder may coexist.-"
CD, a more severe form of
ODD, manifests in severe behavioral problems such as aggression
toward people and animals,
destruction of property, deceitfulness, theft, or serious violation of
rules. Children with bipolar disorder may manifest their irritability in
a violent manner as well. Thus, NPs
need to distinguish between the two
disorders. In children with bipolar
disorder, the onset of irritable,
impulsive outbursts is rapid, whereas in children with ODD or CD, the
onset is slower and progresses ftom
minor infarctions to more severe
rule-breaking. Further, children
with bipolar disorder tend to have
episodic outbursts rather than a
continual progression, and they
generally express guilt and remorse
following an outburst."

When to Refer
In the case of most children and
adolescents, evaluation and management are considered outside the
scope of primary care practice."
Even psychiatrists and other specialists in thefieldof mental health may
take up to 8 years to accurately diagnose bipolar disorder.^' Because
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many patients with bipolar disorder
will first present to a primary care
provider, NPs will still need to provide a preliminary diagnosis and,
possibly, initiate treatment for highly symptomatic patients before making appropriate referral. The

TABLE 2

remainder of this article provides
the information that primary care
NPs need to start the process.

Diagnostic and Medical Evaluation
Physical causes, including medical
conditions (Table 3) and use of cer-

tain pharmacologie agents (Table
4), must be excluded when
patients present with symptoms
consistent with a mood disorder.
In addition, patients with bipolar
disorder, as compared with the
general population, have a higher

MOOD DISORDER QUESTIONNAIRE'

Please answer each questian as best you can. Circle Yes or No.
1. Has there ever been a period of time when you were not your usual self and...
• you felt so good or so hyper that other people thought you were not your normal self or
you were so hyper that you got into trouble?

No
No

• you were so irritable that you shouted at people or started fights or arguments?

Yes
Yes

• you felt much more self-confident than usual?

Yes

No

• you got much less sleep than usual and found you didn't really miss it?

Yes

No

• you were much more talkative or spoke much faster than usual?

Yes

No

• thoughts raced through your head or you couldn't slow your mind down?

Yes

No

• you were so easily distracted by things around you that you had trouble
concentrating or staying on track?

Yes

No

• you had much more energy than usual?

Yes

No

• you were much more active or did many more things than usual?

Yes

No

• you were much more social or outgoing than usual—for example, you telephoned
friends in the middle of the night?

Yes

No

• you were much more interested in sex than usual?

Yes

No

• you did things that were unusual for you or that other people might have thought
were excessive, foolish, or risky?

Yes

No

• spending money got you or your family into trouble?

Yes

No

Yes

No

2. If you circled "Yes" to more than one of the questions above, have several of these
episodes ever happened during the same period of time?
3. How much of a problem did any of these episodes cause you (eg, being unable to work;
having family, money, or legal troubles; getting into arguments or fights)?
Please circle one response only.
No Problem Minor Problem Moderate Problem

Serious Problem

4. Have any of your blood relatives (ie, children, siblings, parents, grandparents,
aunts, uncles) had manic-depressive illness or bipolar disorder?

Yes

No

5. Has a healthcare professional ever told you that you have manic-depressive
illness or bipolar disorder?

Yes

No

Score:
Question 1 ; 7 out of 13 "Yes" responses; Question 2; 1 positive "Yes" response; Question 3; "Moderate" or "Serious"

Positive Screen: All 3 criteria met in Questions 1, 2, and 3.
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lifetime incidence of many medical
conditions, necessitating careful
history taking and performance of a
physical examination before making a diagnosis of bipolar disorder
or beginning a medication regimen.
No single diagnostic study is
used to make the diagnosis of bipolar disorder. However, several laboratory tests must be ordered before
making the diagnosis to rule out an
underlying medical cause that may
mimic or precipitate the depressive
or manic side of bipolar disorder.
Another reason for ordering laboratory tests is to ensure that certain
body systems are functioning adequately; otherwise, patients may
not tolerate medications such as
lithium, anticonvulsants, or "atypical" antipsychotics."
A complete blood cell count
(CBC) with differential will rule
out anemia as a cause of the
depression. These blood tests are
also important because certain
anticonvulsants may depress bone
marrow, and lithium may cause a
reversible increase in the white
blood cell count. A sedimentation

TABLE 3

rate is measured to exclude an
underlying disease process such as
systemic lupus erythematosus
(SLE), infection, or malignancy.'*" If
SLE is suspected, then an antinuclear antibody test is performed. A
fasting glucose level is ordered to
rule out diabetes mellitus; the
atypical antipsychotics have been
associated with both weight gain
and blood glucose dysregulation.
An electrolyte panel is ordered
because (1) hyponatremia may
manifest as depression, (2) lithium
use may cause renal and/or electrolyte problems, and (3) hyponatremia may lead to elevated lithium
levels, possibly resulting in lithium
toxicity. Serum calcium is measured
because hypocalcemia may be associated with mental status changes
and because hypercalcemia is associated with hyperparathyroidism,
which may cause depression.
Serum protein levels are measured
in patients who present with
depression and loss of appetite/
anorexia; low serum protein levels
may affect the way certain medications are metabolized. Thyroid

function tests are performed to rule
out hyperthyroidism (associated
with manic symptoms) and
hypothyroidism (associated with
depressive symptoms)."
A toxicology screen is ordered
because persons who abuse alcohol or other drugs may present
with symptoms of mania or
depression, and because many
patients with bipolar disorder have
a comorbid drug or alcohol addiction that should be uncovered. An
HIV test is considered in persons at
high risk; AIDS causes changes in
mental status, including depression. NPs may also consider ordering tests to check for syphilis,
which alters mental status. Renal
function tests (serum creatinine,
blood urea nitrogen) are performed
to rule out renal dysfunction,
which may present as depression.
A baseline electrocardiogram
(ECG) is obtained because many
antidepressants (especially the tricyclic antidepressants [TCAs]), the
atypical antipsychotics, and lithium can affect the heart and lead
to rhythm abnormalities.'"

MEDICAL CONDITIONS THAT MAY CAUSE CHANGES IN MOOD AND BEHAVIOR

NEUROLOGIC DISORDERS: Seizures, tumors, cerebrovascular accident, subdural hematoma/closed head injury,
neurodegenerative diseases, Parkinson's disease, Huntington's disease, Alzheimer's disease, Wilson's disease
ENDOCRINOLOGIC DISORDERS: Thyroid disease, adrenal disease
METABOLIC DISORDERS: Electrolyte imbalance, uremia, thiamine deficiency, vitamin B12 deficiency, porphyrio,
postoperative status
CARDIAC DISORDERS: Coronary artery disease
IMMUNOLOGIC DISORDERS: Systemic lupus erythematosus, fibromyalgia
DEMYELINATING DISEASE: Multiple sclerosis
MALIGNANCY: Pancreatic cancer, calcium-related multiple myeloma
INFECTIOUS DISEASES: Syphilis, encephalitis, HIV infection, hepatitis A or B, infectious mononucleosis, influenza,
Lyme disease, herpes encephalitis
PHARMACOLOGIC-RELATED AND OTHER TOXICITIES: Acute intoxication or withdrawal from prescribed, over-thecounter, or illicit drugs; heavy metal poisoning; carbon monoxide poisoning
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(MAOIs), and TCAs.'' Some
patients
with psychotic features
In many cases, treatment for bipomay
also
require
treatment with an
lar I disorder is managed by a psyantipsychotic
agent,
including one
chiatrist in an inpatient setting.
of
the
newer
second-generation
Nevertheless, many patients present with less overt symptoms in atypical antipsychotics. Table 5 prothe primary care setting, and some vides an overview of pharmacologpatients may resist seeing a mental ie treatment strategies.^"
Lithium—The first medication
healthcare provider. Thus, primary
used
successfully to treat mania,
care NPs need to know the types of
medications that are available to lithium (Eskalith® and others)
remains a first-line pharmacologie
treat bipolar disorder.
The list includes mood stabilizers option, with data clearly support(eg, lithium), anticonvulsants, and ing its efficacy in reducing suicidal
antidepressants, which include selec- ideation in patients with bipolar
tive serotonin inhibitors (SSRIs), disorder." Lithium may take severmonoamine oxidase inhibitors al weeks to achieve a therapeutic

Pharmacologie Treatment Options

TABLE 4

PHARMACOLOGIC AGENTS THAT MAY INDUCE
MANIA/DEPRESSION

MANIA

Amphetamines
Anticholinergics
Benztropine
Bupropion
Caffeine
Corticosteroids
Cyclosporine
Baclofen
Bromocriptine
DEPRESSION

Acyclovir
Alcohol
Anticonvulsanis
Asparaginase
Baclofen
Barbiturates
Beta-adrenergic blockers
Bromocriptine
Calcium channel blockers
Corticosteroids
Cycloserine
Dapsone
Disopyramide
Disulfiram

Captopril
Cimetidine
Disulfiram
Hydralazine
Isoniazid
Levodopa
Levolfiyroxine
Methylphenidate
Monoamine oxidase inhibitors

Estrogens
Fluoroquinolones
Histamine H2-receptor antagonists
HMG-CoA reductase inhibitors
(statins)
Interferon-alfa
Isotretinoin
Mefloquine
Methyldopa
Metoclopramide
Metrizamide
Metron idazole
Opioids
Progestins
Sulfonamides
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effect; severely impaired patients
may need an additional mood-stabilizing or antipsychotic agent to
treat symptomatology. Side effects
may include nausea, diarrhea,
tremor, polyuria, and polydipsia,
which are managed by reducing
the total daily dose or adjusting the
dosing schedule. Patients on longterm lithium may develop hypothyroidism and, in rare cases, renal
insufficiency. Serum lithium levels
must be monitored judiciously to
prevent neurotoxicity, which may
occur when peak serum levels
exceed 2.0 mEq per L.*" In general, a
serum lithium level range of 0.5 to
1.4 mEq per L is recommended for
acute treatment and prophylaxis.'"
Because lithium is renally excreted,
NPs must exercise caution when
prescribing it in combination with
nonsteroidal anti-inflammatory
drugs, thiazide diuretics, angiotensin-converting enzyme inhibitors or angiotensin II receptor
blockers (these agents may slow
kidney funrtion, causing increased
sertim lithium levels).
Antiepileptic Drugs—AEDs
have become increasingly popular
for patients who need a mood stabilizer. These agents may be used
with lithium or as monotherapy in
patients who have failed lithium
treatment. Valproic acid and its
derivatives (eg, divalproex sodium,
valproate sodium) are considered
first-line agents for patients with
acute manic or mixed episodes, and
are often used for long-term maintenance."* The most common side
effects of valproic acid are nausea,
vomiting, diarrhea, and sedation.
NPs should routinely monitor
patients' serum valproate levels,
liver function, and CBC because
serious adverse events, include
hepatotoxicity, pancreatitis, and
thrombocytopenia, may occur.
Valproic acid must be prescribed

VOL 11 NO.

with caution to reproductive-aged
women because this agent is teratogenic, can induce menstrual irregularities, and can increase the risk of
developing polycystic ovary syndrome.'" Carbamazepine extendedrelease (Tegretol®-XR, Carbatrol®)
has been approved to treat mania,
and lamotrigine has been approved
for maintenance therapy.
Antipsychotics—Atypical (second-generation) antipsychotics, including clozapine (Clozaril®),
olanzapine (Zyprexa®), risperidone
(Risperdal®), quetiapine (Seroquel®),
ziprasidone (Geodon®), and aripiprazole (Abilify®), are commonly
used to treat psychotic symptoms of
bipolar disorder. These agents are
preferable tofirst-generationagents
(eg, haloperidol, chlorpromazine)
because they are less likely to induce
extrapyramidal symptoms (EPS)
such as akathisia and tardive dyskinesia.'" Onset of action is fairly
rapid, and treatment response may
be seen within thefirstweek of use.
Except for clozapine, all of the
atypicals are approved by the Food
and Drug Administration (FDA) as
monotherapy for mania or for use
with mood stabilizers. Olanzapine is
FDA approved for maintenance therapy, and, when used vwth the SSRI
fluoxetine (Prozac®), is approved to
treat bipolar depression. Quetiapine
was recently approved to treat bipolar depression.''
When prescribing atypicals,
NPs need to monitor patients for
EPS, which are managed with anticholinergics, antihistamines, beta
blockers, or benzodiazepines.
Patients using atypicals must also
be monitored for weight gain, diabetes, insulin resistance, and alterations in lipid profiles.'"'
Antidepressants and Anxiolytics—SSRIs, MAOIs, and TCAs are
often used to treat acute depressive
episodes in patients with bipolar
VOL,

disorder or to manage pafients who patients with bipolar disorder than
are lithium refractory." Antidepres- in those with major depressants, with the possible exception of sion.'"" In all scopes of practice,
bupropion (Wellbutrin®), can trig- bipolar disorder is much less recger mania in patients with bipolar ognized than unipolar depression.
disorder, so their use is controver- Approximately 70% of patients
sial.*" Benzodiazepines such as lor- with bipolar disorder have received
azepam (Ativan®) and donazepam at least one misdiagnosis (mean,
(Klonopin®) have been used for 3.5 misdiagnoses).'""' Primary
rapid treatment of agitation, insom- care practitioners are not the only
nia, and anxiety in patients with group of healthcare professionals
manic or hypomanic symptoms with a high rate of misdiagnosis of
until the mood stabilizer they are bipolar disorder; on average, mental
using reaches a therapeutic effect. healthcare providers take up to 8
Patients with comorbid psychiatric years to recognize this illness.'' This
problems should be referred to a delay in diagnosis may be due to the
psychiatric clinician who has exper- fart that ofthe two poles of a bipolar
tise in treating the ñiU spectrum of disorder, mania is more dramatic
psychiatric illnesses.
and has been the major area of
research, to the exclusion of bipolar
depression or mixed states.''""
Cognitive-Behavioral Therapy
Medications alone do not help
NPs should follow a systemic
patients with bipolar disorder treatment plan in managing bipolar
attain optimal levels of function- disorder. This plan may include preing." Recent research has suggested scribing medications and making
that patients with bipolar disorder appropriate referrals to a psychiatric
have better outcomes (eg, reduced clinician or to the ED for hospitallikelihood of relapse, improved ization in the case of acute mania.
adherence to their medication regi- Patients who give any indication
men) when they receive psychother- that they are a danger to themselves
apy such as cognitive-behavioral or to others, who are gravely distherapy (CBT) along with medica- abled or out of control, or who
tion.'"' Patients with bipolar disor- have a concurrent medical condider need to learn skills to cope tion such as liver failure or a cardiac
with psychosocial Stressors that condition that warrants close monimay trigger a symptomatic epi- toring should be hospitalized.-"
sode. CBT can help foster a sense of
Finally, NPs need to help de-stigpersonal empowerment while matize all forms of mental illness,"''
reducing the social stigma of hav- which can be done by developing
ing a mental illness." When treat- supportive relationships with
ing bipolar patients, NPs should patients and their families. Patients
refer them to a professional thera- should be empowered with hope,
pist to supplement the plan of care. education, and support. NPs also
must individualize the treatment
Implications for NPs
plan to the specific characteristics
Misdiagnosing bipolar disorder and patterns of each patient, and
can have serious consequences should keep in mind each patient's
because morbidity and mortality underlying co-morbidities and
(eg, functional impairment, sui- financial and social situations, which
cide) occur at a higher rate in may all affert treatment success."
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Conclusion
Because of the high prevalence of
bipolar disorder, primary care NPs
will likely encounter patients with
this illness in their practice. Each
patient seen for depression and/or

anxiety should be screened for
bipolar disorder. Early detection of
bipolar illness can help patients
reach a stable mood in a shorter
period of time. Developing a therapeutic alliance with patients can
help ensure adherence to the med-

ication regimen. NPs must use a
collaborative approach, referring
patients to experts in psychiatric
illness, as well as therapists to help
teach patients skills to understand
and cope with their illness. An
individualized treatment plan that

BIPOLAR DISORDER PHARMACOLOGIC TREATMENT STRATEGIES^«

TABLE 5

MEDICATION
(EXAMPLES)

MANIA MONOTHERAPY

BIPOLAR DEPRESSION

MAINTENANCE/
PROPHYLAXIS

CONCERNS

Lithium carbonate
(Duralith", Eskalith ,
Lithobid'l

FDA approved. Classic
bipolar 1 symptoms.
May have an antisuicide
effect. Monitoring blood
levels is critical.

Not FDA approved.
Recommended by the
APA guidelines as
first-line therapy.

FDA approved since 1978.
Research has indicated Li
to be better than placebo
in prolonging time to
intervention for a manic
event.

Monitoring blood levels is
critical because of the risk for
toxicity and life-threatening
SE at lithium blood levels
>2.0 mEq/L

FDA approved. Proven
effective in treating and
preventing mania.

Not FDA approved. No
published controlled trials.
May be useful in rapidcycling bipolar disorders
or aggression.

Not FDA approved.
Research suggests better
outcomes than with Li
or placebo (eg, better
medication adherence,
less deterioration (per
symptoms of depression
and GAF scores).

Monitoring of blood levels
needed to determine
therapeutic range. Monitor
for hepatic toxicity, increased
appetite with weight gain.

Anticonvulsants
Divalproex sodium
(Depacon*,
Depakote")

I

Carbamazepine ER
(Carbotrol®, Epitol',
Tegretol*)

FDA approved. Not as
effective as divalproex in
a randomized blind study,"
May be effective in potients
who have not responded to
Li therapy.'-'

Not FDA approved. Two
research studies have
suggested significant
improvement from baseline
in patients with acute
bipolar depression,'

Not FDA approved.
Controversial research
findings when compared
with Li for maintenance
trials, Li superior on
primary measures.
whereas carbamazepine
superior in bipolar patients
with atypical features.

Inconsistency among dose,
serum concentration,
response, and SE. Monitor
hématologie parameters and
liver function tests frequently
during first 2 months of
therapy.

Lamotrigine
(Lamictal*)

Not FDA approved. No
research studies support
ttie use of lamotrigine for
acute mania.

Not FDA approved.
Several research studies
indicate that lamotrigine
is more effective than
placebo in controlling
symptoms of bipolar
depression. Recommended
by APA guidelines as
first-line therapy for acute
bipolar depression.

FDA approved. Two
research studies indicated
a prolonged time to
recurrence of a depressive
episode.

Levels increased by
divalproex sodium. Levels
decreased by carbamazepine
and acetaminophen. Start at
a low dosage and titrate
slowly to reduce risk of
Stevens-Johnson syndrome.
Do not administer to persons
with any type of rash.

'1^1
B
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takes into account the individual's
unique characteristics and underlying comorbidities will help
reduce the financial and social
stigmata of this common mental
health problem. •

TABLE 5

Jane E. Neu is a board certified psychiatric nurse at Natchaug Hospital
and a family nurse practitioner at
Ledgebrook Family Practice, both in
Mansfield Center, Connecticut.
Susan DeNisco is an associate clinical professor and coordinator of the

Family Nurse Practitioner Program
at Sacred Heart University in
Fairfield, Connecticut. The authors
state that they do not have a financial interest in or other relationship
with any commercial product named
in this presentation.

BIPOLAR DISORDER PHARMACOLOGIC TREATMENT STRATEGIES^« (Continued)

MEDICATION
(EXAMPLES)

MANIA MONOTHERAPY

BIPOLAR DEPRESSION

MAINTENANCE/
PROPHYLAXIS

CONCERNS

Not FDA approved. Initial
research suggests clozapine
to be effective.

Not FDA approved.

Not FDA approved.

Sedation+++, weight gain+++.
Of concern: associated
incidence of agranulocytosis,
may lower oral contraceptive
efficacy. Risk of diabetes. QTc
prolongation. Risk for EPS and
NMS.

Olanzapine
(Zyprexa-'l

FDA approved alone or
v/ith Li or valproote to
increase antimanic efficacy.

FDA approved when
combined with fluoxetine.

FDA opproved. May
reduce time to recurrence
of mania or depression.

Sedation++, weight gain+++.
Risk of diabetes and
dyslipidemia. Risk for EPS and
NMS.

Risperidone
(Risperdal*)

FDA approved for short-term
treatment of acute mania or
mixed episodes associated
with bipolar I.

Not FDA approved as
monotherapy. May be
used in combination with
Li or volproate.

Not FDA approved. May
reduce time to recurrence
of mania or depression.

Increased prolactin levels,
weight gain +++. Increased
TG and cholesterol levels. Risk
for EPS and NMS.

Quefiaplne
(Seroquel®)

FDA approved for acute
mania in bipolar I disorder.
May be used in combination
with Li or valproate to
increase antimanic efficacy.
FDA approved os mania
combination therapy.

FDA approved in 2006
for depressive episodes
associoted with bipolar
disorder

Currently under clinical
trial investigation.

Somnolence, dizziness, dry
mouth, constipation. Risk of
weight gain, diabetes, and
dyslipidemia. May increase LFT
values. Risk for EPS and
NMS. Ocular lens changes;
monitor for cataracts q 6 months.

Ziprasidone
(Geodon-)

FDA approved for acute
mania or mixed episodes
associated with bipolar 1.

FDA approved in 2001 for
treatment of schizophrenia
and schizoaffective disorder.
Not FDA approved for
bipolar depression.

Not FDA approved.

Contraindicated in patients with
history of QT prolongation,
recent Ml, CHE Risk of weight
gain, diabetes, and
dyslipidemia. Risk for EPS and
NMS. Monitor electrolytes.
Lower risk of weight gain than
other atypicals.

Aripiprazole

FDA approved for ocute
mania or mixed episodes
associated with bipolar I.

Not FDA approved.

Not FDA approved.
One study demonstrated
effectiveness for 6 weeks
of maintenance therapy
after stabilization of
acute mania.

Somnolence, headoche,
anxiety, insomnia, Gl upset.
Lower risk for obesity,
diabetes, and dyslipidemia thon
other atypicals. Risk for EPS
ond NMS.

Atypical Antlpsychotics
Clozapine
(Clozaril®)

(Abilify'1

FDA = Food and Drug Administration; APA = American Psychiatric Association; Li = lithium; SE = side effects; GAF = globol assessment of functioning;
EPS = extrapyramidol symptoms; NMS = neuroleptic molignant syndrome; TG = triglycérides; L F = liver function test; Ml = myocardial infarction;
CHF = congestive heart failure; Gl = gastrointestinal.
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